P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

• Barbara Eichhorst,
• Nicole Lamanna,
• Susan O’brien,
• Constantine Tam,
• Lugui Qiu,
• Keri Yang,
• Ken Wu,
• Tommi Salmi,
• Gisoo Barnes,
• Jennifer R. Brown

Affiliations

Barbara Eichhorst

1 University of Cologne, Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Department of Internal Medicine, Cologne, Germany

Nicole Lamanna

2 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, United States

Susan O’brien

3 Chao Family Comprehensive Cancer Center, University of California, Irvine, United States

Constantine Tam

4 Alfred Health and Monash University, Melbourne, Australia

Lugui Qiu

5 Poznan University of Medical Sciences, Department of Hematology and Bone Marrow Transplantation, Poznan, Poland

Keri Yang

6 BeiGene USA, Inc., San Mateo, United States

Ken Wu

7 BeiGene (Beijing) Co., Ltd., and BeiGene USA, Inc., Beijing, China

Tommi Salmi

8 BeiGene International, GmbH, Basel, Switzerland

Gisoo Barnes

6 BeiGene USA, Inc., San Mateo, United States

Jennifer R. Brown

9 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, United States